1
|
Jackson N, Hill I, Alhussan A, Bromma K, Morgan J, Abousaida B, Zahra Y, Mackeyev Y, Beckham W, Herchko S, Krishnan S, Chithrani DB. Dual enhancement in the radiosensitivity of prostate cancer through nanoparticles and chemotherapeutics. Cancer Nanotechnol 2023; 14:75. [PMID: 37781236 PMCID: PMC10539438 DOI: 10.1186/s12645-023-00228-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 09/20/2023] [Indexed: 10/03/2023] Open
Abstract
Background Radiotherapy (RT) is an essential component in the treatment regimens for many cancer patients. However, the dose escalation required to improve curative results is hindered due to the normal tissue toxicity that is induced. The introduction of radiosensitizers to RT treatment is an avenue that is currently being explored to overcome this issue. By introducing radiosensitizers into tumor sites, it is possible to preferentially enhance the local dose deposited. Gold nanoparticles (GNPs) are a potential candidate that have shown great promise in increasing the radiosensitivity of cancer cells through an enhancement in DNA damage. Furthermore, docetaxel (DTX) is a chemotherapeutic agent that arrests cells in the G2/M phase of the cell cycle, the phase most sensitive to radiation damage. We hypothesized that by incorporating DTX to GNP-enhanced radiotherapy treatment, we could further improve the radiosensitization experienced by cancer cells. To assess this strategy, we analyzed the radiotherapeutic effects on monolayer cell cultures in vitro, as well as on a mice prostate xenograft model in vivo while using clinically feasible concentrations for both GNPs and DTX. Results The introduction of DTX to GNP-enhanced radiotherapy further increased the radiotherapeutic effects experienced by cancer cells. A 38% increase in DNA double-strand breaks was observed with the combination of GNP/DTX vs GNP alone after a dose of 2 Gy was administered. In vivo results displayed significant reduction in tumor growth over a 30-day observation period with the treatment of GNP/DTX/RT when compared to GNP/RT after a single 5 Gy dose was given to mice. The treatment strategy also resulted in 100% mice survival, which was not observed for other treatment conditions. Conclusions Incorporating DTX to work in unison with GNPs and RT can increase the efficacy of RT treatment. Our study suggests that the treatment strategy could improve tumor control through local dose enhancement. As the concentrations used in this study are clinically feasible, there is potential for this strategy to be translated into clinical settings. Supplementary Information The online version contains supplementary material available at 10.1186/s12645-023-00228-0.
Collapse
Affiliation(s)
- Nolan Jackson
- Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2 Canada
| | - Iona Hill
- Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX 77030 USA
| | - Abdulaziz Alhussan
- Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2 Canada
| | - Kyle Bromma
- Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2 Canada
| | - Jessica Morgan
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8P 5C2 Canada
- Trev and Joyce Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5 Canada
| | - Belal Abousaida
- Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX 77030 USA
| | - Yasmin Zahra
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224 USA
| | - Yuri Mackeyev
- Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX 77030 USA
| | - Wayne Beckham
- Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2 Canada
- British Columbia Cancer-Victoria, Victoria, BC V8R 6V5 Canada
| | - Steven Herchko
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224 USA
| | - Sunil Krishnan
- Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX 77030 USA
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224 USA
| | - Devika Basnagge Chithrani
- Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2 Canada
- Centre for Advanced Materials and Related Technologies, Department of Chemistry, University of Victoria, Victoria, BC V8P 5C2 Canada
- Division of Medical Sciences, University of Victoria, Victoria, BC V8P 5C2 Canada
- Department of Computer Science, Mathematics, Physics and Statistics, Okanagan Campus, University of British Columbia, Kelowna, BC V1V 1V7 Canada
| |
Collapse
|
2
|
Rauta PR, Mackeyev Y, Sanders K, Kim JB, Gonzalez VV, Zahra Y, Shohayeb MA, Abousaida B, Vijay GV, Tezcan O, Derry P, Liopo AV, Zubarev ER, Carter R, Singh P, Krishnan S. Pancreatic tumor microenvironmental acidosis and hypoxia transform gold nanorods into cell-penetrant particles for potent radiosensitization. Sci Adv 2022; 8:eabm9729. [PMID: 36367938 PMCID: PMC9651859 DOI: 10.1126/sciadv.abm9729] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 09/24/2022] [Indexed: 06/16/2023]
Abstract
Coating nanoparticles with stealth epilayers increases circulation time by evading opsonization, macrophage phagocytosis, and reticuloendothelial sequestration. However, this also reduces internalization by cancer cells upon reaching the tumor. We designed gold nanorods (GNRs) with an epilayer that retains stealth properties in circulation but transforms spontaneously in the acidotic tumor microenvironment to a cell-penetrating particle. We used a customized stoichiometric ratio of l-glutamic acid and l-lysine within an amphiphilic polymer of poly(l-glutamic acid-co-l-lysine), or P(Glu-co-Lys), to effect this transformation in acidotic environments. P(Glu-co-Lys)-GNRs were internalized by cancer cells to facilitate potent in vitro radiosensitization. When administered intravenously in mice, they accumulate in the periphery and core of tumors without any signs of serum biochemical or hematological alterations, normal organ histopathological abnormalities, or overt deterioration in animal health. Furthermore, P(Glu-co-Lys)-GNRs penetrated the tumor microenvironment to accumulate in the hypoxic cores of tumors to potently radiosensitize heterotopic and orthotopic pancreatic cancers in vivo.
Collapse
Affiliation(s)
| | - Yuri Mackeyev
- Vivian L. Smith Department of Neurosurgery, UTHealth, Houston, TX, USA
| | - Keith Sanders
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
| | - Joseph B.K. Kim
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
| | | | - Yasmin Zahra
- Vivian L. Smith Department of Neurosurgery, UTHealth, Houston, TX, USA
| | | | - Belal Abousaida
- Vivian L. Smith Department of Neurosurgery, UTHealth, Houston, TX, USA
| | | | - Okan Tezcan
- Vivian L. Smith Department of Neurosurgery, UTHealth, Houston, TX, USA
| | - Paul Derry
- Department of Chemistry, Rice University, Houston, TX, USA
| | - Anton V. Liopo
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
| | | | - Rickey Carter
- Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA
| | - Pankaj Singh
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA
| | - Sunil Krishnan
- Vivian L. Smith Department of Neurosurgery, UTHealth, Houston, TX, USA
| |
Collapse
|
3
|
Abousaida B, Seneviratne D, Hoppe BS, Ko SJ, Asaithamby A, Cucinotta FA, Kirwan JM, Mody K, Toskich B, Ashman JB, Hallemeier CL, Krishnan S. Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021; 8:1169-1179. [PMID: 34595139 PMCID: PMC8478421 DOI: 10.2147/jhc.s292516] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 09/08/2021] [Indexed: 01/22/2023] Open
Abstract
Localized hepatocellular carcinoma (HCC) that is unresectable and non-transplantable can be treated by several liver-directed therapies. External beam radiation therapy (EBRT) is an increasingly accepted and widely utilized treatment modality in this setting. Accelerated charged particles such as proton beam therapy (PBT) and carbon ion radiation therapy (CIRT) offer technological advancements over conventional photon radiotherapy. In this review, we summarize the distinct advantages of CIRT use for HCC treatment, focusing on physical and biological attributes, and outline dosimetric and treatment planning caveats. Based on these considerations, we posit that HCC may be among the best indications for use of CIRT, as it allows for maximizing tumoricidal doses to the target volume while minimizing the dose to the organs at risk.
Collapse
Affiliation(s)
- Belal Abousaida
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA
| | | | - Bradford S Hoppe
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA
| | - Stephen J Ko
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA
| | - Aroumougame Asaithamby
- Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Francis A Cucinotta
- School of Integrated Health Sciences, University of Las Vegas, Las Vegas, NV, USA
| | - Jessica M Kirwan
- Department of Radiation Oncology, University of Florida, Gainesville, FL, USA
| | - Kabir Mody
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, FL, USA
| | - Beau Toskich
- Division of Interventional Radiology, Department of Radiology, Mayo Clinic Florida, Jacksonville, FL, USA
| | - Jonathan B Ashman
- Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
| | | | - Sunil Krishnan
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA
| |
Collapse
|